NovaBridge Biosciences (NBP) grants options and RSUs to executive
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NovaBridge Biosciences director and Chief Business Development Officer Cao Sean Wuxiong received new equity awards. He was granted 181,290 employee share options to buy Ordinary Shares (via American Depositary Shares) at an exercise price of $1.53 per ADS, expiring on June 22, 2036. These options vest in eight equal quarterly installments only after the 30-trading-day weighted average price of the company’s ADS is at or above $8.00.
He also received 181,280 restricted share units, each representing a contingent right to receive one ADS. These RSUs vest over four years, with one-fourth vesting on September 3, 2026 and the remainder vesting ratably over the following 12 quarters.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Cao Sean Wuxiong
Role
Chief Bus. Development Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Units | 181,280 | $0.00 | -- |
| Grant/Award | 2025 Employee Share Option (right to buy) | 181,290 | $0.00 | -- |
Holdings After Transaction:
Restricted Share Units — 181,280 shares (Direct, null);
2025 Employee Share Option (right to buy) — 181,290 shares (Direct, null)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive one American Depositary Shares ("ADS"). Number of underlying securities and exercise price expressed in terms of ADSs. The RSUs shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00.
Key Figures
Employee share options granted: 181,290 options
Option exercise price: $1.53 per ADS
Option expiration: June 22, 2036
+4 more
7 metrics
Employee share options granted
181,290 options
Grant on June 22, 2026 to Cao Sean Wuxiong
Option exercise price
$1.53 per ADS
Exercise price for 2025 Employee Share Option grant
Option expiration
June 22, 2036
Expiration date for granted employee options
RSUs granted
181,280 RSUs
Grant on June 22, 2026 to Cao Sean Wuxiong
RSU initial vest date
September 3, 2026
One-fourth of RSUs vest on this date
Performance vesting price
$8.00 ADS price
30-day average ADS price needed for option vesting
ADS to Ordinary ratio
10 ADSs = 23 Ordinary Shares
Representation ratio for NovaBridge Ordinary Shares
Key Terms
Restricted Share Units, American Depositary Shares, 30-trading-day weighted average price, Employee Share Option, +1 more
5 terms
30-trading-day weighted average price financial
"the 30-trading-day weighted average price of the Issuer's ADS ... is at or above US$8.00."
contingent right financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one American Depositary Shares"
FAQ
What equity awards did NovaBridge Biosciences (NBP) grant to Cao Sean Wuxiong?
NovaBridge Biosciences granted Cao Sean Wuxiong 181,290 employee share options and 181,280 restricted share units. Both awards relate to Ordinary Shares represented by American Depositary Shares, providing a mix of performance-based and time-based equity incentives.
What are the key terms of the new stock options reported for NBP?
The new options cover 181,290 underlying Ordinary Shares via ADSs, with an exercise price of $1.53 per ADS and expiration on June 22, 2036. Vesting occurs in eight quarterly installments after the ADS 30-day average price reaches $8.00.
What does each RSU granted by NovaBridge Biosciences (NBP) represent?
Each restricted stock unit represents a contingent right to receive one American Depositary Share. The filing notes the Ordinary Shares may be represented by ADSs, with 10 ADSs corresponding to 23 Ordinary Shares of NovaBridge Biosciences.
Is the equity grant to NovaBridge Biosciences (NBP) executive a market purchase or compensation?
The transactions are compensation-related grants, not market purchases. They are coded as “A” for grant, award, or other acquisition, with zero transaction price per share, reflecting employee stock options and restricted share units awarded to the executive.